1378260-92-4

Basic information

• Product Name: 1,7-NAPHTHYRIDINE-4-CARBOXYLIC ACID
• Synonyms: 1,7-NAPHTHYRIDINE-4-CARBOXYLIC ACID
• CAS NO: 1378260-92-4
• Molecular Formula: C9H6N2O2
• Molecular Weight: 174.15614
• Mol File: 1378260-92-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 385.8±22.0 °C(Predicted)
• Appearance: /
• Density: 1.421±0.06 g/cm3(Predicted)
• PKA: 0.29±0.10(Predicted)
• CAS DataBase Reference: 1,7-NAPHTHYRIDINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1,7-NAPHTHYRIDINE-4-CARBOXYLIC ACID(1378260-92-4)
• EPA Substance Registry System: 1,7-NAPHTHYRIDINE-4-CARBOXYLIC ACID(1378260-92-4)

Safety Data

• Hazardous Substances Data: 1378260-92-4(Hazardous Substances Data)

Usage

General Description

1,7-Naphthyridine-4-carboxylic acid is a chemical compound with the molecular formula C12H8N2O2. It is a heterocyclic aromatic carboxylic acid that contains a naphthyridine ring system. 1,7-NAPHTHYRIDINE-4-CARBOXYLIC ACID is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has potential applications in the development of new drugs, as it exhibits biological activity and is known to be a potent inhibitor of bacterial DNA gyrase enzymes. Additionally, 1,7-naphthyridine-4-carboxylic acid has been studied for its potential use as a corrosion inhibitor and as a fluorescent probe for the detection of metal ions in biological samples.

Upstream product

• 60122-51-2 1,7-naphthyridin-4(1H)-one 
• 1584652-43-6 1,7-naphthyridine-4-carbonitrile 
• 58680-40-3 4-bromo-1,7-naphthyridine 

Relevant articles and documents

Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)

Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV). It has been convincingly linked to multiple disease states involving remodeling of the extracellular matrix. FAP inhibition is investigated as a therapeutic option for several of these diseases, with most attention so far devoted to oncology applications. We previously discovered the N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors. In the present study, we explore in detail the structure-activity relationship around this core scaffold. We report extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP) the log D values, plasma stabilities, and microsomal stabilities of selected compounds were found to be highly satisfactory. Pharmacokinetic evaluation in mice of selected inhibitors demonstrated high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo.